PMID: 11903411Mar 21, 2002Paper

Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes

Diabetes, Obesity & Metabolism
A JönssonA Melander

Abstract

To study the effects and serum levels of glibenclamide (Gb) and its active metabolites in patients on chronic Gb medication on different daily doses. Fifty patients with type 2 diabetes on regular Gb therapy (1.75-14.0 mg daily). Blood samples were taken immediately before and 90 min after regular Gb intake. A standardized breakfast was served 30 min after drug intake. Serum insulin and proinsulin levels were determined by ELISA methods without cross-reactivities. Serum drug levels were determined by HPLC. Fischer's R to Z-test (correlation coefficients) and paired Student t-tests were used when comparing values within the entire group and unpaired non-parametric Mann-Whitney tests were used when comparing high and low dose levels. A p-value < 0.05 was considered significant. There were significant correlations between daily Gb dose, on the one hand, and, on the other, HbAlc (r = 0.55), Delta-insulin (r = - 0.59) and Delta-proinsulin (r = - 0.52) levels. Significant correlations between Gb therapy duration and insulin (r = - 0.40) and proinsulin (r = - 0.34) secretion and between Gb dose and ratio proinsulin/insulin (RPI) at both time points (r = 0.32 and 0.30) were also found. The RPI was lower after Gb intake. In patients on ...Continue Reading

References

May 11, 1992·Diabetes Care·R M CohenR S Clements
Feb 1, 1973·The Journal of Clinical Pharmacology and New Drugs·L M FuccellaG Valzelli
Oct 1, 1972·The Journal of Clinical Endocrinology and Metabolism·W C DuckworthA E Kitabchi
Jun 1, 1983·Diabetologia·K AsplundF Lithner
Jan 1, 1982·European Journal of Clinical Pharmacology·E Wåhlin-BollB Scherstén
Apr 1, 1994·Diabetic Medicine : a Journal of the British Diabetic Association·M J DaviesI P Gray
Feb 1, 1993·Annals of Internal Medicine·S StenmanL C Groop
Jun 1, 1997·Diabetes Research and Clinical Practice·I InoueS Katayama
Apr 29, 1998·European Journal of Clinical Pharmacology·A JönssonA Melander

❮ Previous
Next ❯

Citations

Sep 26, 2012·Experimental Diabetes Research·Liping ZhuJerry Yee
Jul 15, 2009·Bioorganic & Medicinal Chemistry·Vincenzo CalderoneAldo Balsamo
Apr 28, 2007·Biochemical Pharmacology·Olga L ZharikovaMahmoud S Ahmed
Nov 3, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·A Nybäck-NakellL Landstedt-Hallin
Jul 22, 2014·Phytotherapy Research : PTR·Prasad NeeratiAnil Kumar Gangi
Jun 28, 2005·Drugs·Virendra Rambiritch, Poobalan Naidoo
Apr 26, 2017·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rui LiManthena V S Varma
Nov 6, 2002·Progress in Cardiovascular Nursing·James S Zebrack, Jeffrey L Anderson
Apr 10, 2003·American Journal of Physiology. Endocrinology and Metabolism·Mikael LehtihetAke Sjoholm
Oct 5, 2018·Frontiers in Immunology·Chidchamai KewcharoenwongGanjana Lertmemongkolchai
Nov 7, 2007·Southern Medical Journal·Virendra RambiritchNeil Butkow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.